Patients in the program | All (n = 53) |
---|---|
Age, years | |
Mean ± SD | 45.8 ± 15.3 |
Min/Max | 16/78 |
Men, n(%) | 20(38 %) |
Occupational status, n (%) | |
Occupational activity | 23 (43 %) |
Sickness pension | 7 (13 %) |
Duration of severe asthma, years | |
Mean ± SD | 13 ± 10.8 |
Median | 10 |
Min/Max | 1/52 |
Allergy, n (%) | |
Dust mites | 50 (94 %) |
Moulds | 19 (36 %) |
Cat | 36 (68 %) |
Dog | 23 (43 %) |
Other animals | 12 (23 %) |
Serum tIgE, IU/ml | |
Mean ± SD | 251 ± 219 |
Median | 174 |
Min/Max | 30/922 |
N ≥ 76 IU/ml, n (%) | 40 (76 %) |
ICS dose, mcg/day | |
Mean ± SD | 2912 ± 1262 |
Median | 2500 |
Min/Max | 1500/8500 |
OCS dose, mg/day | |
Regularly useda, n (%) | 38 (72 %) |
Mean | 16 ± 12.6 |
Median | 10 |
Min/Max | 0/50 |
Complications after OCS, n (%) | 30 (57 %) |
Arterial hypertension | 10 (19 %) |
Diabetes | 8 (15 %) |
Osteoporosis | 7 (13 %) |
Cataract | 3 (6 %) |
Glaucoma | 2 (4 %) |
Cushingoid appearance | 9 (17 %) |
Adrenocortical insufficiency | 1 (2 %) |
Other | 4 (8 %) |
Additional control drugs, n (%) | |
LABA | 47 (89 %) |
LTRA | 39 (74 %) |
SAMA/LAMA | 16 (30 %) |
Theophylline | 12 (23 %) |
Severe exacerbations/year, n | |
Min 3, n (%) | 53 (100 %) |
Mean ± SD | 5.6 ± 4 |
Median | 4 |
Min/Max | 3/24 |
Hospitalizations in the preceding year, n (%) | 24 (45 %) |
Life-threatening asthma, n (%) | 23 (43 %) |
ACQ points | |
Mean ± SD | 3.3 ± 1.1 |
Median | 3.4 |
Min/Max | 1.6/5.4 |
AQLQ points | |
Mean ± SD | 3.4 ± 1.2 |
Median | 3 |
Min/Max | 1.6/6.5 |
FEV1% within normal limits | |
Mean ± SD | 64.6 ± 26.1 |
Median | 59 |
Min/Max | 23/136 |